Biosimilar Pipeline Report 2H 2024

IPD Analytics has released its Biosimilar Pipeline Report, which provides insight on potential approvals and launches across the biosimilar landscape over the 2024–2027 horizon.

During 1H 2024, the FDA approved 14 new biosimilars, including biosimilars referencing Humira, Stelara, Prolia, Soliris, Eylea, and Actemra. The growing pipeline of near-term biosimilar approvals and launches will further drive use and savings. Lower-cost biosimilars are playing a critical role in controlling drug spend, as biologics continue to be a leading driver of increasing healthcare costs.

As expected, as utilization of biosimilars increases, we note a trend of decreasing average sales prices (ASPs) of both reference products and those biosimilar products that have ASPs.

Of the 21 drugs covered in the report, notable impacts to utilization, pricing, and market share are expected for Stelara, Xolair, Prolia, Soliris, Eylea, and Neulasta.

Learn more by registering to read the report.